Join our daily newsletter At The Bell to receive exclusive market insights
- Biotron (BIT) launches a human trial of its lead antiviral drug against COVID-19
- The trial of Biotron’s BIT225 compound has been approved as a sub-study of an ongoing phase two HIV-1 clinical trial, which is currently in progress in Thailand
- Biotron has enrolled 27 people into the HIV-1 clinical trial, but should any of the volunteers be diagnosed with symptomatic COVID-19 infection during the six-month treatment period, they will subsequently be enrolled into the COVID-19 sub-study
- The company says it anticipates results to be released by mid-2023
- Biotron is up 6.19 per cent and trading at 6 cents at 11:53 am AEST
Biotron (BIT) has launched a human trial of its lead antiviral drug against COVID-19.
The trial of Biotron’s BIT225 compound has been approved as a sub-study of an ongoing phase two HIV-1 clinical trial, which is currently in progress in Thailand.
BIT225 has previously demonstrated both antiviral and immunomodulatory effects in its current development for HIV-1 and has recently demonstrated clinical benefits against SARS-CoV-2 in an accepted murine model of disease.
Biotron has enrolled 27 people into the HIV-1 clinical trial. Should any of these volunteers be diagnosed with symptomatic COVID-19 during the six-month treatment period, they will subsequently be enrolled into the COVID-19 sub-study.
Biotron Managing Director Michelle Miller said the company was very pleased to be able to incorporate an assessment of BIT225 against SARS-CoV-2 infection into its ongoing clinical trial.
“There are minimal additional costs associated with the sub-study and no expected impact on the timing of the results of the BIT225-010 trial as it is fully recruited,” Dr Miller said.
“The sub-study provides a speedy and cost-effective pathway to explore the potential benefit of BIT225 against SARS-CoV-2 in a high-risk patient population.”
Participants in the COVID-19 sub-study will continue on the HIV-1 trial throughout the sub-study and after the sub-study’s conclusion.
The company said it anticipated results to be reported by mid-2023.
Biotron was up 6.19 per cent and trading at 6 cents at 11:53 am AEST.
